O
CHRS icon

OrbiMed’s Coherus Oncology CHRS Stock Holding History

OrbiMed’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,722,400
Closed -$28.4M – 134
2018
Q3 		$28.4M Buy
1,722,400
+241,918
+16% +$4.29M 0.34% 76
2018
Q2 		$20.7M Buy
1,480,482
+13,682
+0.9% +$196K 0.25% 89
2018
Q1 		$16.2M Sell
1,466,800
-4,700
-0.3% -$51.4K 0.2% 87
2017
Q4 		$12.9M Buy
1,471,500
+391,800
+36% +$4.19M 0.16% 95
2017
Q3 		$14.4M Hold
1,079,700
– – 0.14% 96
2017
Q2 		$15.5M Sell
1,079,700
-4,700
-0.4% -$90.4K 0.16% 89
2017
Q1 		$22.9M Buy
1,084,400
+234,300
+28% +$5.76M 0.26% 75
2016
Q4 		$23.9M Buy
850,100
+178,500
+27% +$5M 0.3% 62
2016
Q3 		$18M Buy
+671,600
New +$18.3M 0.2% 78

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's CHRS Position: Q4 2018 in Review

OrbiMed sold out of Coherus Oncology (CHRS) in Q4 2018, closing a stake of 1,722,400 shares — an estimated $28.4M sold.

OrbiMed first reported a position in CHRS in Q3 2016 and held it in 9 quarters. The position peaked at $28.4M in Q3 2018. 111 funds tracked by Wall St. Rank hold CHRS as of Q4 2018.

  • OrbiMed reported no remaining Coherus Oncology position as of Q4 2018 after selling out during the quarter.
  • OrbiMed sold 1,722,400 Coherus Oncology shares in Q4 2018, an estimated $28.4M.
  • OrbiMed first reported a position in Coherus Oncology in Q3 2016 and held it in 9 quarters.
  • OrbiMed's Coherus Oncology position peaked at $28.4M in Q3 2018.
  • 111 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.